The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Commentary|Articles|March 6, 2026
February Roundup of FDA Approvals in Oncology: 6 Decisions to Know
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic options that were given the green light by the FDA in February 2026. The regulatory roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights detailing clinical practice implications.
Related to this article
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Advertisement
Advertisement